Phase III Trial On Concurrent And Adjuvant Temozolomide Chemotherapy In Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. (RTOG 0834)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Sep 2017
At a glance
- Drugs Temozolomide (Primary)
- Indications Anaplastic astrocytoma; Glioma; Oligodendroglioma
- Focus Registrational; Therapeutic Use
- Acronyms CATNON
- 10 Aug 2017 Results of the pre-specified interim analysis (n=745; As of 31 May 2015) published in The Lancet
- 26 Jul 2017 Planned End Date changed from 16 Sep 2015 to 1 Jan 2024.
- 26 Jul 2017 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2022.